Advertisement
New Zealand markets closed
  • NZX 50

    11,796.21
    -39.83 (-0.34%)
     
  • NZD/USD

    0.5893
    -0.0012 (-0.21%)
     
  • NZD/EUR

    0.5529
    -0.0016 (-0.28%)
     
  • ALL ORDS

    7,817.40
    -81.50 (-1.03%)
     
  • ASX 200

    7,567.30
    -74.80 (-0.98%)
     
  • OIL

    83.70
    +0.97 (+1.17%)
     
  • GOLD

    2,408.60
    +10.60 (+0.44%)
     
  • NASDAQ

    17,394.31
    -99.31 (-0.57%)
     
  • FTSE

    7,840.18
    -36.87 (-0.47%)
     
  • Dow Jones

    37,775.38
    +22.07 (+0.06%)
     
  • DAX

    17,669.24
    -168.16 (-0.94%)
     
  • Hang Seng

    16,219.47
    -166.40 (-1.02%)
     
  • NIKKEI 225

    37,068.35
    -1,011.35 (-2.66%)
     
  • NZD/JPY

    90.9700
    -0.2840 (-0.31%)
     

Better Gene Sequencing Stock: Illumina vs. Bionano Genomics

Better Gene Sequencing Stock: Illumina vs. Bionano Genomics

Illumina (NASDAQ: ILMN) and Bionano Genomics (NASDAQ: BNGO) might both make gene sequencing devices, but as investments the two couldn't be more different. Whereas Bionano is a new entrant to the market and still has a lot to prove to its investors as well as the scientific community, Illumina is the top dog that's fighting to maintain its position. Bulls argue that Illumina is the better gene sequencing stock because in some sequencing markets, it's basically the only option in town, particularly in the all-important market for next generation sequencers (NGS).